Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD) - PR Newswire

Submitted by Anonymous (not verified) on Tue, 05/27/2025 - 12:00

Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)  PR Newswire